To evaluate the relative efficacy of a non-degradable osmotic slow-release
dosage form containing 6.6 mg
cetylpyridinium chloride (MOTS [Mucosal Oral Therapeutic System]
CPC) to inhibit new plaque formation and
gingivitis, a single-blind, randomised, parallel group pilot study was set up. 52 healthy volunteers were assigned to receive one of the following treatments for 18 days of non-brushing: holding 1 MOTS
CPC 2 x daily for 2 h intra-orally, or rinsing 30 s with 15 ml
Peridex 2 x daily, or dissolve Cepacol (each 1.6 mg
CPC) lozenges 2 x daily unsupervised. Before the test period, the subjects received a thorough tooth cleaning followed by tooth polishing 1 x a week for 3 weeks to achieve clinical gingival health. After the start of
therapy, the subjects were examined at day 4, 7 (+/- 2), 14 (+/- 2) and 18 (2 +/-). Relative efficacy was assessed by the modified Navy plaque index, the Quigley and Hein index, the planimetric plaque index, as well as the papillary marginal gingival index. There was an increase in both plaque formation and
gingivitis over the 18 +/- 2 day period of nonbrushing for all subjects in the study.
Peridex was the most effective in inhibiting plaque and
gingivitis formation over that period of time. There was no difference between MOTS
CPC and Cepacol at any time point in plaque accumulation and
gingivitis intensity.
Peridex was considered more convenient than MOTS
CPC. Cepacol resulted in more staining at 18 days than MOTS
CPC and
Peridex.